CSPC Pharmaceutical Announces 2020 Interim Results
Profit Attributable To Shareholders Increased 23.2% to RMB2,314 Million Declared An Interim Dividend of HK6 Cents Per Share Proposed A Bonus Issue of 3 Bonus Shares For Every 5 Existing Shares Held HONG KONG, Aug. 26, 2020 /PRNewswire/ -- CSPC Pharmaceutical Group Limited (HKEx: 01093) ("CSPC P...
CSPC Pharmaceutical Announces 2019 Annual Results
Profit Attributable To Shareholders Increased 20.6% to RMB3,714 Million Innovative Drug Business Continued to Deliver Strong Growth New Products Launched Helped to Sustain Growth HONG KONG, March 30, 2020 /PRNewswire/ -- CSPC Pharmaceutical Group Limited (HKEx: 01093) ("CSPC Pharmaceutical" or the...
CSPC Pharmaceutical Announces 2019 Interim Results
Profit Attributable To Shareholders Increased 24.8% to RMB1,878 Million Innovative Drug Business Continued to Deliver Strong Growth R&D Investment Increased Significantly HONG KONG, Aug. 19, 2019 /PRNewswire/ -- CSPC Pharmaceutical Group Limited (HKEx: 01093) ("CSPC Pharmaceutical" or the "Group")...
CSPC Pharmaceutical Announces 2018 Annual Results
* Profit Attributable To Shareholders Increased 31.9% to HK$3,655 Million * Innovative Drug Business Continued to Deliver Strong Growth * R&D Deployment Further Improved HONG KONG, March 18, 2019 /PRNewswire/ -- CSPC Pharmaceutical Group Limited (HKEx: 01093) ("CSPC Pharmaceutical" or the "G...
CSPC Pharmaceutical Announces 2018 Interim Results
* Profit Attributable To Shareholders Increased 41.1% to HK$1,853 Million * Innovative Drug Business Continued to Deliver Strong Growth * Common Generic Drug Business Increased Market Penetration * Bulk Drug Business Kept Market Leader Position; R&D Deployment Further Improved HONG KONG,...
CSPC Pharmaceutical Announces 2017 Annual Results
Profit Attributable To Shareholders Increased 31.9% to HK$2,771 Million Innovative Drug Business Continued to Deliver High Growth Common Generic Drug Business Maintained Stable Growth Vitamin C Bulk Drug Business Showed Strong Recovery HONG KONG, March 19, 2018 /PRNewswire/ -- CSPC Pharma...
CSPC Pharmaceutical Announces 2017 Interim Results
HONG KONG, Aug. 22, 2017 /PRNewswire/ -- CSPC Pharmaceutical Group Limited (HKEx: 1093) ("CSPC Pharmaceutical" or the "Group"), a leading pharmaceutical company inChina, is pleased to announce its interim results for the six months ended30 June 2017 (the "Period"). During the Period, the Group re...
CSPC Pharmaceutical Announces 2016 Annual Results
Profit attributable to shareholders increased 26.2% to HK$2,101 million Innovative Drug Business Maintained Strong Growth Momentum Common Generic Drug Business Continued to Deliver Stable Growth Bulk Drug Business Maintained Leading Position in the Industry HONG KONG, March 20, 2017 /PRNewswire...
CSPC Pharmaceutical Announces 2016 Interim Results
HONG KONG, Aug. 23, 2016 /PRNewswire/ -- CSPC Pharmaceutical Group Limited (HKEx: 1093) ("CSPC Pharmaceutical" or the "Group"), a leading pharmaceutical company inChina, is pleased to announce its interim results for the six months ended30 June 2016 (the "Period"). During the Period, the Group re...
CSPC Pharmaceutical Announces 2015 Annual Results
HONG KONG, March 21, 2016 /PRNewswire/ -- CSPC Pharmaceutical Group Limited (HKEx: 1093) ("CSPC Pharmaceutical" or the "Group"), a leading pharmaceutical company inChina, is pleased to announce its annual results for the year ended 31 December 2015 (the "Year"). The Group recorded sales revenue o...
CSPC Pharmaceutical Announces 2015 Interim Results
HONG KONG, Aug. 25, 2015 /PRNewswire/ -- CSPC Pharmaceutical Group Limited (HKEx: 1093) ("CSPC Pharmaceutical" or the "Group"), a leading pharmaceutical company inChina, is pleased to announce its interim results for the six months ended30 June 2015 (the "Period"). During the Period, the Group re...
